Acuta Capital Partners, LLC Dyne Therapeutics, Inc. Transaction History
Acuta Capital Partners, LLC
- $92.9 Million
- Q2 2024
A detailed history of Acuta Capital Partners, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 212,500 shares of DYN stock, worth $6.13 Million. This represents 8.08% of its overall portfolio holdings.
Number of Shares
212,500
Previous 184,500
15.18%
Holding current value
$6.13 Million
Previous $5.24 Million
43.19%
% of portfolio
8.08%
Previous 4.28%
Shares
5 transactions
Others Institutions Holding DYN
# of Institutions
203Shares Held
105MCall Options Held
82.7KPut Options Held
24.8K-
Atlas Venture Life Science Advisors, LLC8.02MShares$231 Million37.7% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$226 Million40.83% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$213 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY6.39MShares$184 Million3.76% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$175 Million3.22% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.49B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...